NAMSNewAmsterdam Pharma Company N.V.

NAMS Stock Price, Valuation & Chart | NewAmsterdam Pharma Company N.V.

Compare

$25.590+0.67 (+2.69%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology NAMS intrinsic value NAMS calculated fair value vs price

Overview Financials Dividends Ratios

NAMS Historical price chart

NAMS Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.99B

PE Ratio-11.85

EPS-2.16

Trading Volume979.90K

Today's High/Low26.01/25.0

Dividend Yield0.00

52 Week High/Low42.2/23.05

Shares Outstanding116.90M

NAMS Financial Statement

NAMS Analyst ratings

NAMS Analysis & performance metrics

NAMS Company profile

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead…

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at…

NAMS Management team

Name

Position

Juliette Audet M.B.A., M.Sc.

Chief Strategy & Business Officer

Mayur Amrat SomaiyaCFO

Chief Financial Officer

Matthew Philippe

Executive Vice President &Head of Investor Relations

Louise Kooij

Chief Accounting Officer

Marc Ditmarsch M.D.

Chief Development Officer

Maryellen McQuade

Chief People Officer

Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.CTO

Founder, Chief Scientific Officer, Member of Executive Board & Director

Douglas F. KlingCOO

Chief Operating Officer

Name

Position

Juliette Audet M.B.A., M.Sc.

Chief Strategy & Business Officer

Mayur Amrat SomaiyaCFO

Chief Financial Officer

Matthew Philippe

Executive Vice President &Head of Investor Relations

Louise Kooij

Chief Accounting Officer

Marc Ditmarsch M.D.

Chief Development Officer

Maryellen McQuade

Chief People Officer

Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.CTO

Founder, Chief Scientific Officer, Member of Executive Board & Director

Douglas F. KlingCOO

Chief Operating Officer

Management Team

Juliette Audet M.B.A., M.Sc.

Chief Strategy & Business Officer

Mayur Amrat SomaiyaCFO

Chief Financial Officer

Matthew Philippe

Executive Vice President &Head of Investor Relations

Louise Kooij

Chief Accounting Officer

Marc Ditmarsch M.D.

Chief Development Officer

Maryellen McQuade

Chief People Officer

Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.CTO

Founder, Chief Scientific Officer, Member of Executive Board & Director

Douglas F. KlingCOO

Chief Operating Officer

Management

Juliette Audet M.B.A., M.Sc.

Chief Strategy & Business Officer

Mayur Amrat SomaiyaCFO

Chief Financial Officer

Matthew Philippe

Executive Vice President &Head of Investor Relations

Louise Kooij

Chief Accounting Officer

Marc Ditmarsch M.D.

Chief Development Officer

Maryellen McQuade

Chief People Officer

Johannes Jacob Pieter Kastelein FESC, M.D., Ph.D.CTO

Founder, Chief Scientific Officer, Member of Executive Board & Director

Douglas F. KlingCOO

Chief Operating Officer

Total 8 executives

NAMS Frequently asked questions

What is NewAmsterdam Pharma Company N.V. (NAMS) Stock Price?

Current stock price of NewAmsterdam Pharma Company N.V. (NAMS) stock is $25.590. The stock price is +2.69% higher in the session. The intraday range can be seen from this page. Volume of NewAmsterdam Pharma Company N.V. (NAMS) stock is 979.90K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the NewAmsterdam Pharma Company N.V. (NAMS) stock price going up or down today?

The stock price of NewAmsterdam Pharma Company N.V. (NAMS) can change with earnings, company news, and overall market sentiment. NewAmsterdam Pharma Company N.V. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the NewAmsterdam Pharma Company N.V. stock expensive at its current price?

Whether NewAmsterdam Pharma Company N.V. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for NAMS on this page is -11.85. EPS on this page is -2.16. Compare those figures with peers and growth expectations before deciding if the current NewAmsterdam Pharma Company N.V. price is justified.

How has the stock price of NewAmsterdam Pharma Company N.V. (NAMS) performed historically?

Historical performance for NewAmsterdam Pharma Company N.V. (NAMS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how NAMS reacted to past earnings and market events.

Should I buy NewAmsterdam Pharma Company N.V. (NAMS) stock, at this price?

Buying NewAmsterdam Pharma Company N.V. (NAMS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.